Sign in or create an account to add this stock to your watchlist.
About CymaBay Therapeutics (NASDAQ:CBAY)
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops arhalofenate, which has completed five Phase II clinical trials for the treatment of patients with gout; and MBX-2982, an oral G-protein coupled receptor agonist that has completed one Phase II clinical trial for therapeutic indications. It has licensing agreement with Kowa Pharmaceuticals America, Inc. for the development and commercialization of arhalofenate in the United States; and Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders, as well as a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CBAY
CUSIPN/A
Phone510-293-8800
Debt
Debt-to-Equity Ratio0.01
Current Ratio12.91
Quick Ratio12.91
Price-To-Earnings
Trailing P/E Ratio-15.70
Forward P/E Ratio-11.07
P/E GrowthN/A
Sales & Book Value
Annual Sales$10 million
Price / Sales72.87
Cash FlowN/A
Price / CashN/A
Book Value$1.53 per share
Price / Book8.10
Profitability
EPS (Most Recent Fiscal Year)($0.79)
Net Income$-27,550,000.00
Net MarginsN/A
Return on Equity-40.66%
Return on Assets-34.13%
Miscellaneous
Employees26
Outstanding Shares58,770,000
CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions
What is CymaBay Therapeutics' stock symbol?
CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."
How were CymaBay Therapeutics' earnings last quarter?
CymaBay Therapeutics (NASDAQ:CBAY) announced its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.18. View CymaBay Therapeutics' Earnings History.
When is CymaBay Therapeutics' next earnings date?
What price target have analysts set for CBAY?
11 Wall Street analysts have issued 1 year target prices for CymaBay Therapeutics' stock. Their forecasts range from $15.00 to $27.00. On average, they anticipate CymaBay Therapeutics' stock price to reach $18.7778 in the next twelve months. View Analyst Ratings for CymaBay Therapeutics.
What are Wall Street analysts saying about CymaBay Therapeutics stock?
Here are some recent quotes from research analysts about CymaBay Therapeutics stock:
- 1. According to Zacks Investment Research, "CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. " (5/22/2018)
- 2. HC Wainwright analysts commented, "EASL; Phase 3 Initiation in 2H18 on Track; Affirm Buy Stock Data 03/27/2018 Price $12.00 Exchange NASDAQ Price Target $18.00 52-Week High $15.59 52-Week Low $3.16 Enterprise Value (M) $611.7 Market Cap (M) $702 Public Market Float (M) 19.5 Shares Outstanding (M) 58.5 3 Month Avg Volume 980,454 Short Interest (M) 2.59 Balance Sheet Metrics Cash (M) $97.2 Total Debt (M) $6.9 Total Cash/Share $1.66 Book Value/Share $2.16 Cash (M): Amount shown is as of December 31 and does not include the $135.5M net proceeds from the recent equity raise.. EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.29) (0.20) (0.21) 2Q (0.30) (0.31) (0.22) 3Q (0.25) (0.21) (0.25) 4Q (0.30) (0.11) (0.27) FY (1.14) (0.79) (0.95) Revenue ($M) Full Year – Dec 2016A 2017A 2018E 1Q 0.0 4.8 0.0 2Q 0.0 0.0 0.0 3Q 0.0 0.0 0.0 4Q 0.0 5.2 0.0 FY 0.0 10.0 5.0 20 15 10 5 0 MAR- 17 J UL- 17 NOV- 17 MAR- 18 12 10 8 6 4 2 0 Vol." (3/28/2018)
- 3. Cantor Fitzgerald analysts commented, "Clarity on Phase 3 PBC trial design should come before end of 2Q18. Management noted that discussions with U.S. and European regulators are ongoing and expressed pleasure with the level of engagement. Once the details have been finalized, the company expects to share them with the Street. High level, the company anticipates conducting a single pivotal study involving a treatment period of 12 months." (3/16/2018)
Who are some of CymaBay Therapeutics' key competitors?
Some companies that are related to CymaBay Therapeutics include Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT), The Medicines (MDCO), Heron Therapeutics (HRTX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), OPKO Health (OPK) and Evotec A.G. (EVTCY).
Who are CymaBay Therapeutics' key executives?
CymaBay Therapeutics' management team includes the folowing people:
- Dr. Robert James Wills, Exec. Chairman (Age 64)
- Dr. Charles A. McWherter Ph.D., Sr. VP & Chief Scientific Officer (Age 63)
- Dr. Pol F. Boudes M.D., Ph.D., Chief Medical Officer (Age 61)
- Mr. Sujal A. Shah, Pres, CEO & Director (Age 45)
- Mr. Daniel Menold, Principal Financial Officer, Principal Accounting Officer & VP - Fin. (Age 48)
Has CymaBay Therapeutics been receiving favorable news coverage?
Media headlines about CBAY stock have been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. CymaBay Therapeutics earned a news impact score of 0.06 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 45.92 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are CymaBay Therapeutics' major shareholders?
CymaBay Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (5.03%), Foresite Capital Management IV LLC (3.59%), Franklin Resources Inc. (3.06%), Foresite Capital Management III LLC (2.66%), BlackRock Inc. (1.99%) and Millennium Management LLC (1.97%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Charles Mcwherter, Kurt Von Emster, Robert James Wills and Sujal Shah. View Institutional Ownership Trends for CymaBay Therapeutics.
Which major investors are selling CymaBay Therapeutics stock?
CBAY stock was sold by a variety of institutional investors in the last quarter, including Abingworth LLP, Farallon Capital Management LLC, Foresite Capital Management IV LLC, Barclays PLC, DAFNA Capital Management LLC, Baird Financial Group Inc., Alpine Global Management LLC and California Public Employees Retirement System. Company insiders that have sold CymaBay Therapeutics company stock in the last year include Carl Goldfischer and Kurt Von Emster. View Insider Buying and Selling for CymaBay Therapeutics.
Which major investors are buying CymaBay Therapeutics stock?
CBAY stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Foresite Capital Management III LLC, Redmile Group LLC, BlackRock Inc., Artal Group S.A., Citadel Advisors LLC, Franklin Resources Inc. and Nexthera Capital LP. Company insiders that have bought CymaBay Therapeutics stock in the last two years include Charles Mcwherter, Robert James Wills and Sujal Shah. View Insider Buying and Selling for CymaBay Therapeutics.
How do I buy shares of CymaBay Therapeutics?
Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CymaBay Therapeutics' stock price today?
One share of CBAY stock can currently be purchased for approximately $12.40.
How big of a company is CymaBay Therapeutics?
CymaBay Therapeutics has a market capitalization of $756.94 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-27,550,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. CymaBay Therapeutics employs 26 workers across the globe.
How can I contact CymaBay Therapeutics?
CymaBay Therapeutics' mailing address is 7999 GATEWAY BLVD SUITE 130, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected]
MarketBeat Community Rating for CymaBay Therapeutics (CBAY)
MarketBeat's community ratings are surveys of what our community members think about CymaBay Therapeutics and other stocks. Vote "Outperform" if you believe CBAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
CymaBay Therapeutics (NASDAQ:CBAY) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for CymaBay Therapeutics in the last 12 months. Their average twelve-month price target is $18.7778, suggesting that the stock has a possible upside of 51.43%. The high price target for CBAY is $27.00 and the low price target for CBAY is $15.00. There are currently 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $18.7778 | $18.7778 | $16.5556 | $14.00 |
| Price Target Upside: | 51.43% upside | 43.12% upside | 35.15% upside | 68.07% upside |
CymaBay Therapeutics (NASDAQ:CBAY) Consensus Price Target History
CymaBay Therapeutics (NASDAQ:CBAY) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
CymaBay Therapeutics (NASDAQ:CBAY) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
CymaBay Therapeutics (NASDAQ CBAY) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.50%
Institutional Ownership Percentage: 82.05%
CymaBay Therapeutics (NASDAQ CBAY) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/11/2018 | Sujal Shah | CEO | Buy | 5,000 | $10.65 | $53,250.00 | 90,000 |  |
| 3/22/2018 | Carl Goldfischer | Director | Sell | 15,000 | $13.03 | $195,450.00 | 9,340 | |
| 3/5/2018 | Kurt Von Emster | Director | Sell | 13,353 | $15.51 | $207,105.03 | 90,000 | |
| 2/14/2018 | Kurt Von Emster | Director | Sell | 218,057 | $15.89 | $3,464,925.73 | | |
| 2/7/2018 | Kurt Von Emster | Director | Sell | 40,763 | $12.35 | $503,423.05 | 90,000 | |
| 2/5/2018 | Kurt Von Emster | Director | Sell | 18,831 | $12.14 | $228,608.34 | | |
| 2/2/2018 | Kurt Von Emster | Director | Sell | 90,098 | $12.15 | $1,094,690.70 | | |
| 1/31/2018 | Kurt Von Emster | Director | Sell | 97,639 | $12.22 | $1,193,148.58 | 90,000 | |
| 1/25/2018 | Kurt Von Emster | Director | Sell | 39,438 | $12.18 | $480,354.84 | 90,000 | |
| 1/22/2018 | Kurt Von Emster | Director | Sell | 138,253 | $10.40 | $1,437,831.20 | 90,000 | |
| 1/19/2018 | Kurt Von Emster | Director | Sell | 144,216 | $10.25 | $1,478,214.00 | 90,000 | |
| 1/5/2018 | Kurt Von Emster | Director | Sell | 4,300 | $10.21 | $43,903.00 | 90,000 | |
| 12/22/2017 | Kurt Von Emster | Director | Sell | 173,192 | $9.41 | $1,629,736.72 | 90,000 | |
| 11/10/2017 | Kurt Von Emster | Director | Sell | 50,048 | $9.26 | $463,444.48 | 90,000 | |
| 11/2/2017 | Carl Goldfischer | Director | Sell | 18,000 | $8.66 | $155,880.00 | 9,000 | |
| 11/2/2017 | Charles Mcwherter | SVP | Buy | 5,000 | $8.67 | $43,350.00 | 10,300 | |
| 10/31/2017 | Kurt Von Emster | Director | Sell | 59,209 | $9.27 | $548,867.43 | 90,000 | |
| 10/3/2017 | Kurt Von Emster | Director | Sell | 108,876 | $7.85 | $854,676.60 | | |
| 9/29/2017 | Kurt Von Emster | Director | Sell | 211,124 | $8.09 | $1,707,993.16 | | |
| 8/1/2017 | Robert James Wills | Director | Buy | 5,000 | $6.84 | $34,200.00 | 25,200 | |
| 7/20/2017 | Charles Mcwherter | SVP | Buy | 5,000 | $7.43 | $37,150.00 | 5,100 | |
| 7/20/2017 | Sujal Shah | Insider | Buy | 10,000 | $7.34 | $73,400.00 | 75,891 | |
| 9/6/2016 | Robert James Wills | Director | Buy | 25,000 | $2.43 | $60,750.00 | 25,000 | |
| 4/15/2016 | Charles Mcwherter | VP | Buy | 3,000 | $1.68 | $5,040.00 | 5,000 | |
| 4/5/2016 | Sujal Shah | CFO | Buy | 55,000 | $1.39 | $76,450.00 | 42,000 | |
| 4/4/2016 | Sujal Shah | CFO | Buy | 22,000 | $1.39 | $30,580.00 | 42,000 | |
| 9/11/2015 | Carl Goldfischer | Director | Sell | 46,729 | $2.74 | $128,037.46 | | |
| 8/14/2015 | Emster Kurt Von | Director | Buy | 90,000 | $2.69 | $242,100.00 | | |
| 7/20/2015 | Emster Kurt Von | Director | Buy | 1,600,000 | $2.81 | $4,496,000.00 | | |
| 5/18/2015 | Sujal Shah | CFO | Buy | 10,000 | $3.40 | $34,000.00 | | |
| 5/18/2015 | Wart Harold Van | CEO | Buy | 7,500 | $3.34 | $25,050.00 | | |
| 5/15/2015 | Charles Mcwherter | VP | Buy | 2,000 | $3.16 | $6,320.00 | | |
(Data available from 1/1/2013 forward)
CymaBay Therapeutics (NASDAQ CBAY) News Headlines
| Source: |
|
CymaBay Therapeutics (NASDAQ:CBAY) SEC Filings
This page is loading this company's SEC Filings. Please wait...
CymaBay Therapeutics (NASDAQ:CBAY) Income Statement, Balance Sheet and Cash Flow Statement
CymaBay Therapeutics (NASDAQ CBAY) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
